Targets › IL23A
13 programs from 11 companies in 162 trials: 49 Phase 2, 46 Phase 3, 45 Phase 4, 22 Phase 1; Immunology, Other, Gastroenterology; next expected readout Dec 2026.
Associates with IL12B to form the pro-inflammatory cytokine IL-23 that plays different roles in innate and adaptive immunity. Released by antigen-presenting cells such as dendritic cells or macrophages, binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R to activate JAK2 and TYK2 which then phosphorylate the receptor to form a docking site leading to the phosphorylation of STAT3 and STAT4. (UniProt, Q9NPF7)
Open in Phaseline: the race on IL23A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of California, San Francisco | Intravenous TXA Interleukin-23 inhibitor | ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4 | Phase 4 | Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke … | Dec 2026 |
| University of Calgary | CBD 100 mg OD Interleukin-23 inhibitor | CNR1, PLAT, IL12B, IL23A, ADRB2, HTR2A, NR3C1, TNF, PTGS2, PTGS1 | Phase 4 | Copd; Ehlers-Danlos Syndrome; Crohn Disease; Vasovagal Syncope … | Dec 2026 |
| Johnson & Johnson (Janssen) | Guselkumab (CNTO1959) Interleukin-23 inhibitor | IL12B, IL23A | Phase 4 | Arthritis, Psoriatic; Psoriasis; Colitis, Ulcerative; Crohn's Disease … | Dec 2026 |
| Eli Lilly | Mirikizumab (LY3074828) Interleukin-23 inhibitor | IL12B, IL23A | Phase 4 | Lactation; Crohn's Disease; Ulcerative Colitis; Colitis, Ulcerative … | Feb 2027 |
| Psoriasis Treatment Center of Central New Jersey | Ilumya IL-23 inhibitor | IL23A | Phase 4 | Psoriasis | – |
| Sixth Affiliated Hospital, Sun Yat-sen University | Interleukin-23 monoclonal antibody IL-23 inhibitor; anti-IL-23 monoclonal antibody | IL23A | Phase 4 | Crohn's Disease and Ulcerative Colitis | – |
| AbbVie | Risankizumab Interleukin-23 inhibitor | IL12B, IL23A | Phase 3 | Psoriatic Arthritis; Crohn's Disease; Ulcerative Colitis; Crohn's Disease (CD) … | Jan 2027 |
| Sun Pharmaceutical Industries | Tildrakizumab Interleukin-23 inhibitor | IL12B, IL23A | Phase 3 | Active Psoriatic Arthritis; Moderate to Severe Genital Psoriasis; Psoriatic Arthritis; Moderate-to-severe Chronic Plaque Psoriasis | Feb 2027 |
| Johnson & Johnson (Janssen) | Ustekinumab Interleukin-12 inhibitor; Interleukin-23 inhibitor | IL12B, IL12A, IL23A | Phase 3 | Crohn Disease; Psoriasis; Crohn Disease (CD); Type 1 Diabetes Mellitus … | Sep 2027 |
| Qilu Pharmaceutical | QL2106 injection IL-23 inhibitor | IL23A | Phase 3 | Plaque Psoriasis | Dec 2027 |
| Johnson & Johnson (Janssen) | JNJ-78934804 IL-23 inhibitor | IL23A | Phase 3 | Crohn Disease; Colitis, Ulcerative; Crohn's Disease | Jun 2028 |
| Innovent Biopharmaceutical Technology (Hangzhou) | IBI112 IL-23 inhibitor | IL23A | Phase 3 | Psoriasis | Jan 2029 |
| Chong Kun Dang Pharmaceutical | CKD-704 Risankizumab biosimilar; anti-IL-23 monoclonal antibody | IL23A | Phase 1 | Psoriasis | – |
Crohn's Disease (12) Psoriasis (11) Crohn Disease (10) Ulcerative Colitis (9) Colitis, Ulcerative (5) Psoriatic Arthritis (4) Crohn Disease (CD) (3) Psoriasis Vulgaris (3) Nicotine Dependence (3) Ulcerative Colitis (UC) (2) Pouchitis (2) Arthritis, Psoriatic (2)
antibody (5), small molecule (5), protein or peptide (2), mixed (1)
Johnson & Johnson (Janssen) (3) AbbVie (1) Eli Lilly (1) Sun Pharmaceutical Industries (1) Sixth Affiliated Hospital, Sun Yat-sen University (1) University of California, San Francisco (1) University of Calgary (1) Chong Kun Dang Pharmaceutical (1) Innovent Biopharmaceutical Technology (Hangzhou) (1) Psoriasis Treatment Center of Central New Jersey (1) Qilu Pharmaceutical (1)
IL12B (7) ADRB2 (2) NR3C1 (2) HTR2A (2) AGTR1 (1) PDCD1 (1) MAP2K1 (1) MAP2K2 (1) MS4A1 (1) CHRM3 (1) CHRM2 (1) ADRB3 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.